Please note: The University of Texas Health Science Center at San Antonio will now be called "UT Health San Antonio."

Search Program Faculty/Research

A. Pratap Kumar, Ph.D.

Pratap kumar home image

RESEARCH

The objective of Dr. Pratap Kumar's research program is two-fold. Firstly, he identifies deregulated molecular mechanisms involved in development, progression, and dissemination of cancer. Secondly, he develops intervention strategies to target the identified mechanisms for translation to the bedside. 

He uses cell culture and preclinical animal models of prostate and pancreatic cancers to study the transcriptional regulatory networks associated with fibrosis, inflammation and hormonal signaling. Androgen-independent prostate cancer is the most aggressive and not well-understood form of prostate cancer. There is a great need to find strategies to prevent progression to hormone-independent state. 

Ongoing efforts in his lab have led to the identification of a transcriptional network in androgen-independent prostate cancer as well as compounds that can be used as tools to target players involved in the network. An example of his translational research was the seminal discovery from his work that led to a clinical trial to test the use NexrutineR from cork tree as a radiation therapy adjuvant for prostate cancer patients. Fibrosis is an impediment for clinical management of pancreatic cancer patients. 

On the basic science level, his work has identified GLI transcription factors as important players in pancreatic stellate cells (stroma) and pancreatic cancer cells that may be involved in fibrosis. Very encouragingly on the translational side, he has found a natural extract and its active component that appear to inhibit fibrosis in a preclinical animal model of pancreatic cancer. From these studies, he has also identified a novel role for EP4 in human pancreatic cancer.

Selected Publications

Gong, JJ., Munoz, AR., Chan, D., Ghosh, R and Kumar, AP. 2014. STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth. Oncotarget. (in press).

Li G, Rivas P, Bedolla R, Thapa D, Reddick RL, Ghosh R, Kumar AP. Dietary resveratrol prevents development of high-grade prostatic intraepithelial neoplastic lesions: involvement of SIRT1/S6K axis. Cancer Prev Res (Phila). 2013 Jan;6(1):27-39.

Gong J, Xie J, Bedolla R, Rivas P, Chakravarthy D, Freeman JW, Reddick R, Kopetz S, Peterson A, Wang H, Fischer SM, Kumar AP. Combined Targeting of STAT3/NF-κB/COX-2/EP4 for Effective Management of Pancreatic Cancer. Clin Cancer Res. 2014 Mar 1;20(5):1259-73. This article was selected as highlights of the issue.

Chen CL, Mahalingam D, Osmulski P, Jadhav RR, Wang CM, Leach RJ, Chang TC, Weitman SD, Kumar AP, Sun L, Gaczynska ME, Thompson IM, Huang TH. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer.Prostate. 2013 Jun;73(8):813-26.

Li G, Rivas P, Bedolla R, Thapa D, Reddick RL, Ghosh R, Kumar AP. Dietary resveratrol prevents development of high-grade prostatic intraepithelial neoplastic lesions: involvement of SIRT1/S6K axis. Cancer Prev Res (Phila). 2013 Jan;6(1):27-39.

Bedolla RG, Gong J, Prihoda TJ, Yeh IT, Thompson IM, Ghosh R, Kumar AP. Predictive value of Sp1/Sp3/FLIP signature for prostate cancer recurrence. PLoS One. 2012;7(9):e44917.

Professor
Urology

Education

Ph.D., Life Sciences, University of Hyderabad, 1989

M.S., Microbiology, G.B. Pant University of Agriculture and Technology, 1983

B.S., Zoology and Chemistry, Osmania University, 1980

Contact

Email: KUMARA3@UTHSCSA.EDU

Phone: (210) 562-4116


Research Profile
More Info...

Graduate Students

Shih-Bo Huang